Agreement signedAgreed 13 Nov 2022

Indivior /
Opiant Pharmaceuticals, Inc.

Indivior PLC completes merger with Opiant Pharmaceuticals, Inc.

Price per share
$8.00/share
Stage
Agreement signed
Buy side: Indivior
Buy sideIndivior
Target: Opiant Pharmaceuticals, Inc.
TargetOpiant Pharmaceuticals, Inc.
Source · 13 Nov 2022
Buy side: Indivior
Buy sideIndivior
Target: Opiant Pharmaceuticals, Inc.
TargetOpiant Pharmaceuticals, Inc.
01 / BuyerIndivior
02 / TargetOpiant Pharmaceuticals, Inc.
01

What happened

Indivior PLC’s subsidiary, Indivior Inc., merged with Opiant Pharmaceuticals, Inc., which became a wholly owned subsidiary of Indivior Inc. Opiant stockholders received $20.00 in cash per share, plus a contingent value right tied to product sales milestones.

The contingent value right represents potential payments of up to $8.00 per share.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Indivior PLC completes merger with Opiant Pharmaceuticals, Inc.

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.